Fidelity Investments
AVTX icon

Fidelity Investments’s Avalo Therapeutics AVTX Stock Holding History

Fidelity Investments’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.3M Buy
5,100,216
+2,220,735
+77% +$35.1M ﹤0.01% 1243
2026
Q1 		$43M Buy
2,879,481
+2,659,181
+1,207% +$41.6M ﹤0.01% 1494
2025
Q4 		$4M Buy
+220,300
New +$3.72M ﹤0.01% 2357
2024
Q4 		– Sell
-1
Closed -$9 – 5544
2024
Q3 		$9 Sell
1
-1
-50% -$10 ﹤0.01% 5434
2024
Q2 		$25 Buy
+2
New +$26 ﹤0.01% 5149
2023
Q1 		– Hold
0
– -$66 – 5270
2022
Q4 		– Hold
0
– – – 4916
2022
Q3 		– Hold
0
– – – 4834
2022
Q2 		– Hold
0
– – – 4667
2022
Q1 		– Hold
0
– – – 4940

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments's AVTX Position: Q2 2026 in Review

Fidelity Investments increased its Avalo Therapeutics (AVTX) stake by 77% in Q2 2026, buying an estimated $35.1M and bringing the position to 5,100,216 shares worth $94.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1243.

Fidelity Investments first reported a position in AVTX in Q2 2024 and has held it in 5 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Fidelity Investments held 5,100,216 shares of Avalo Therapeutics worth $94.3M as of Q2 2026.
  • Fidelity Investments bought 2,220,735 Avalo Therapeutics shares in Q2 2026, an estimated $35.1M.
  • Avalo Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1243 holding.
  • Fidelity Investments first reported a position in Avalo Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.